Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.

Grifols appointed an executive chairman on Monday, as the Spanish pharmaceutical company strives to recover from a pandemic-related hit and a 49% drop in its shares so far this year.

Through its Alexion subsidiary, AstraZeneca is acquiring Lexington, Mass.-based LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts in genomics and rare diseases.

The U.S. Supreme Court on Monday declined to hear Biogen Inc’s (BIIB.O) bid to win reinstatement of a patent on the company’s blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc. subsidiary (VTRS.O) Mylan Pharmaceuticals Inc.

Say what you will about the $158,000 price tag on Amylyx’s newly minted Relyvrio or the worthiness of the CENTAUR trial, the FDA’s approval of its third-ever ALS drug has ignited the growing momentum in the space.     

Myovant Sciences announced Sunday it formed a special committee of independent directors to assess Sumitovant Biopharma’s offer to acquire the company, and ultimately, turned the offer down.

LEO Pharma A/S, a global leader in medical dermatology, has launched AD Days Around the World, a global disease awareness campaign that highlights the experiences of people living with atopic dermatitis (AD) – the most common form of eczema.

Moderna Inc. has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday, citing people familiar with the matter.

The biopharma world – and markets – spent Thursday evening reacting as the FDA gave the green light to only its third-ever drug for ALS, Amylyx’s AMX0035. 

Intercept Pharmaceuticals

Intercept Pharmaceuticals Inc. said on Friday its treatment for patients with advanced liver scarring due to non-alcoholic steatohepatitis (NASH) failed to meet the main goal of a late-stage study, sending its shares down as much as 21%.